Research Summary: KRAS G12C mutations occur in a substantial subset of advanced non-small cell lung cancer (NSCLC), and current first-line standards based on immune checkpoint inhibitors (ICIs), with or without chemotherapy, yield suboptimal long-term outcomes. Olomorasib is an orally bioavailable, highly selective KRAS G12C inhibitor...
Read MoreResearch Summary: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are B-cell malignancies that frequently affect older adults and often require prolonged use of Bruton tyrosine kinase inhibitor (BTKi) therapy in the relapsed or refractory (R/R) setting. Ibrutinib and acalabrutinib are both recommended BTKis...
Read MoreResearch Summary: Capivasertib is a potent, selective inhibitor of all three protein kinase B (AKT1/2/3) isoforms. The phosphoinositide 3- kinase/protein kinase B pathway is frequently overactivated in many solid tumors, including hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) breast cancer. In the...
Read MoreResearch Summary: Covalent Bruton tyrosine kinase (BTK) inhibitors have become the preferred treatment for chronic lymphocytic leukemia (CLL). However, the first-generation BTK inhibitor ibrutinib, though effective, has been associated with cardiac toxicity, including atrial fibrillation, heart failure, and sudden death. Acalabrutinib, a second-generation, more selective...
Read MoreResearch Summary: Accurate prognostic assessment in patients with cutaneous melanoma is essential as it is one of the most prevalent malignancies in the United States. The American Joint Committee on Cancer (AJCC) staging system remains the cornerstone of risk stratification, but outcomes vary widely among...
Read MoreResearch Summary: Cutaneous melanoma is a significant public health concern, as it is the fifth most common cancer in the United States. Traditional prognostic assessment relies on clinicopathologic features such as Breslow thickness, ulceration status, and mitotic rate, but these factors do not always accurately...
Read More
Romanos Sklavenitis-Pistofidis, MD, shares the advances in the field of...
Read More
Dr. Pedro Barata discusses the positive impact of cabozantinib+nivolumab treatment...
Read More
Dr. Vincent Xu discusses the safety and tolerability outcomes from...
Read More
Monica White, RN, discusses adverse events that could occur in...
Read More
Dr. Yasser Ged discusses five-year follow-up data from the CheckMate-9ER...
Read More
Hagen Kennecke, a medical oncologist and professor of medicine at...
Read More
Dr. Okolo discusses some of the new tools and advancements...
Read More
Dr. Hagen Kennecke discusses the use of cabozantinib in the...
Read More©2026 Oncology Matrix. All Rights Reserved.
